Revenue: ₹8,545 crore (~11% YoY increase)
Net Profit (PAT): ₹1,418 crore (~2% YoY growth)
North America generics revenue declined ~11% to ₹3,412 crore due to pricing pressures, while Europe surged 142% YoY
Consensus estimates (SimplyWall.st): Average target at ₹1,289, with bullish/bearish range ₹1,660–₹990. Growth forecast modest (~2.9% revenue CAGR through 2026) — down from 13% historical average
Despite milestones in revenue, margins remain under pressure from global competition
For long-term investors: A conservative growth stock with moderate dividend income—best suited for those seeking stability with exposure to generics in key markets.
For traders or momentum players: Watch India- and Europe-driven growth and pipeline developments. U.S. competition remains a major swing factor.
Net Profit (PAT): ₹1,418 crore (~2% YoY growth)
North America generics revenue declined ~11% to ₹3,412 crore due to pricing pressures, while Europe surged 142% YoY
Consensus estimates (SimplyWall.st): Average target at ₹1,289, with bullish/bearish range ₹1,660–₹990. Growth forecast modest (~2.9% revenue CAGR through 2026) — down from 13% historical average
Despite milestones in revenue, margins remain under pressure from global competition
For long-term investors: A conservative growth stock with moderate dividend income—best suited for those seeking stability with exposure to generics in key markets.
For traders or momentum players: Watch India- and Europe-driven growth and pipeline developments. U.S. competition remains a major swing factor.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.